(Q34671630)

3 August 2017

1 reference

title

Rhodium and its compounds as potential agents in cancer treatment (English)

1 reference

3 August 2017

1 reference

Katsaros N

1

1 reference

3 August 2017

Anagnostopoulou A

series ordinal

2

1 reference

3 August 2017

publication date

1 June 2002

1 reference

Critical Reviews in Oncology Hematology

3 August 2017

published in

1 reference

3 August 2017

volume

42

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

297-308

1 reference

Platinum Compounds: a New Class of Potent Antitumour Agents

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

New tumor-inhibiting metal complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Complexes of metals other than platinum as antitumour agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Non-platinum chemotherapeutic metallopharmaceuticals

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Vinblastine, ifosfamide, and gallium nitrate--an active new regimen in patients with advanced carcinoma of the urothelium. A phase II trial of the Eastern Cooperative Oncology Group (E5892).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Vinblastine, ifosfamide, gallium nitrate, and filgrastim in platinum- and paclitaxel-resistant ovarian cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Investigations into the antitumour activity of organotin compounds. I. Diorganotin dihalide and di-pseudohalide complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antitumour action of planar, organometallic rhodium(I) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Phase I trial of weekly scheduling and pharmacokinetics of titanocene dichloride in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Structure, Recognition, and Processing of Cisplatin-DNA Adducts.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Metal complexes as photo- and radiosensitizers

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Correlation between cytotoxicity and DNA binding of polypyridyl ruthenium complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antineoplastic activity of three ruthenium derivatives against chemically induced colorectal carcinoma in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

New tumor-inhibiting metal complexes. Chemistry and antitumor properties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Preclinical activity of trans-indazolium[tetrachlorobisindazoleruthenate(III)] (NSC 666158; IndCR; KP 1019) against tumour colony-forming units and haematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effects of cis -Dichlorodiammineplatinum (II) and Related Transition Metal Complexes on Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effects of the Ru(III) complexes [mer-RuCl3(DMSO)2Im]degrees and Na[trans-RuCl4(DMSO)Im] on solid mouse tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

X-ray structure of [Ru3 O2 (NH3)14]6+, cation of the cytological reagent ruthenium red

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Studies of rhodium(II) carboxylates as potential antitumor agents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Hydrophobicity of several rhodium(II) carboxylates correlated with their biologic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Encapsulation and release of rhodium(II) citrate and its association complex with hydroxypropyl-beta-cyclodextrin from biodegradable polymer microspheres

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

The interaction of Rh(II) and Rh(III) with DNA.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

A circular dichroism and fluorescence quenching study of the interactions between rhodium(II) complexes and human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Interaction of tetra-mu-acetatodirhodium(II) with human serum albumin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Studies on the interaction between human serum albumin and [Rh2(OAc)2(bpy)2(H2O)2](OAc)2.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antitumor effect of the new rhodium (II) complex: Rh2 (form)2 (O2 CCF3)2 (H2O)2 (form = N,N'-di-p-tolyl formamidinate)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Water Soluble Cyclophosphamide Adducts of Rhodium(II) Keto-Gluconate and Glucuronate. Synthesis, Characterization and In Vitro Cytostatic Assays

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Survival and Histopathological Study of Animals Bearing Ehrlich Tumor Treated With a Rhodium(II) Amidate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Rh(2)(CF(3)CONH)(4): The First Biological Assays of a Rhodium (II) Amidate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Water-soluble rhodium(II) carboxylate adducts: cytotoxicity of the new compounds

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Structure of the anti-cancer drug complex tetrakis(μ-acetato)-bis(1-methyladenosine)dirhodium(II) monohydrate

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

The interaction between radiation and complexes of cis-Pt(II) and Rh(II): studies at the molecular and cellular level

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effects of two pyridinalalkyliminerhodium(I) complexes in mice bearing MCa mammary carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

The novel use of Rh(I) complexes with naphthyridine ligands and poly(oxyethylene) as antitumorals

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichlorodiammino platinum(II) in mice bearing Lewis lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antitumor action of rhodium (I) and iridium (I) complexes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Antineoplastic activity of a rhodium trichloride complex of oxalyl homocysteine thiolactone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effect of a rhodium complex on alterations of hepatic function in thioacetamide-induced hyperplastic noduligenesis in rats.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Effects of an antitumoural rhodium complex on thioacetamide-induced liver tumor in rats. Changes in the activities of ornithine decarboxylase, tyrosine aminotransferase and of enzymes involved in fatty acid and glycerolipid synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

A versatile mismatch recognition agent: specific cleavage of a plasmid DNA at a single base mispair

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Long-term follow-up of Ru-106/Rh-106 brachytherapy for posterior uveal melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

106Ru/106Rh plaque radiotherapy for malignant melanomas of the choroid. With follow-up results more than 5 years

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Results after beta-irradiation (106Ru/106Rh) of choroidal melanomas. Twenty years' experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

beta-Irradiation of choroidal melanoma with 106Ru/106Rh applicators. 16 Years' experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Fluorescein angiography in the follow-up study of choroidal melanoma after 106Ru/106Rh plaque therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

[Optimization of irradiation time in the treatment of malignant melanoma of the choroid with beta applicators (106Ru/106Rh)]

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Radiation effects on the optic nerve observed after brachytherapy of choroidal melanomas with 106Ru/106Rh plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

[A beta ray applicator (106Ru/106Rh) in the treatment of ciliary body melanomas]

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

Metal complexes of bleomycin: evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900222-0

7 January 2021

10.1016/S1040-8428(01)00222-0

Identifiers

DOI

1 reference

3 August 2017

1 reference